FDA already has a comprehensive set of questions on a “new paradigm” for nonprescription drug approvals “under conditions of safe use,” but myriad additional questions will emerge on issues ranging from approval standards and enforcement of potential restrictions to how the products are accessed by consumers.
Industry stakeholders, pharmacy experts and consumer health advocates will present on and discuss innovative routes to nonprescription status at FDA’s...
Welcome to HBW Insight
Create an account to read this article
Already a subscriber?